-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-930 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IK-930 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IK-930 in Non-Small Cell Lung Cancer Drug Details: IK-930 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-930 in Malignant Mesothelioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IK-930 in Malignant Mesothelioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IK-930 in Malignant Mesothelioma Drug Details:IK-930 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IK-930 in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IK-930 in Soft Tissue Sarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.IK-930 in Soft Tissue Sarcoma Drug Details:IK-930 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin Mesylate in Ovarian Cancer Drug Details: Eribulin mesylate (E-7389, Halaven,Teceris) is a microtubule dynamics...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Malignant Fibrous Histiocytoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Malignant Fibrous Histiocytoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Malignant Fibrous Histiocytoma Drug Details: Eribulin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Leiomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Leiomyosarcoma Drug Details: Eribulin mesylate (E-7389, Halaven,Teceris) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Non-Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Non-Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Non-Rhabdomyosarcoma Drug Details: Eribulin mesylate (E-7389, Halaven,Teceris) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Peripheral Nerve Sheath Tumor...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Pleomorphic Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Pleomorphic Liposarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Pleomorphic Liposarcoma Drug Details: Eribulin mesylate (E-7389,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eribulin Mesylate in Fibrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eribulin Mesylate in Fibrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eribulin mesylate in Fibrosarcoma Drug Details: Eribulin mesylate (E-7389, Halaven,Teceris) is...